Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for TNBC
NCT05949021Phase 2Active, not recruiting
- Sponsor
- Mridula George
- Start
- Oct 2023
- Primary completion
- Sep 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in triple-negative breast cancer (TNBC), sponsored by Mridula George. Primary endpoint: Disease-Free Survival Rate at 5 years. Started Oct 2023; status: active, not recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05949021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949021.